A Phase 3 trial of CCX168 in Complement 3 Glomerulopathy (C3G)
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Avacopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Registrational; Therapeutic Use
- Sponsors ChemoCentryx
- 23 May 2017 According to a ChemoCentryx media release, the company is planning to initiate this trial in mid-2017.
- 20 Jan 2017 New trial record
- 09 Jan 2017 According to a ChemoCentryx media release, if successful, the study could support registration of the drug.